Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

OMass Technologies Ltd.

OMass Therapeutics is a private biopharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. *


Period Start 2016-01-01 established (s-off)
Period End 2018-11-21 renamed
  Group OMass Therapeutics Ltd.
  Today OMass Therapeutics Ltd.
  Predecessor University of Oxford
  Successor OMass Therapeutics Ltd.
Products Industry drug discovery
  Industry 2 mass spectrometry (MS)
Person Person Robinson, Carol (Univ Oxford 201004 Physical and Theoretical Chemistry Laboratory + OMass)
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street Heatley Road
Oxford Science Park, The Schrödinger Building
  City OX4 4GE Oxford, Oxfordshire
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: 
Record changed: 2023-07-10


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for OMass Therapeutics Ltd.

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group World of Partnering Opportunities 650x300px

» top